[68Ga]Ga-PentixaFor

Phase 2

NNational Cancer Institute (NCI)

[68Ga]Ga-PentixaFor is one of 6 therapeutic programs targeting Hyperaldosteronism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HyperaldosteronismRecruiting

HyperaldosteronismPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Hyperaldosteronism

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

2 2

Baxfendy

AstraZeneca

Phase 3

1 3

LCI699

Novartis

Phase 2

1 4

Ga-Pentixafor

NNantes University Hospital

Phase 2

1 5

[68Ga]Ga-PentixaFor

NNational Cancer Institute (NCI)

Phase 2

1 6

Aldosterone Antagonist

IImperial College London

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Hyperaldosteronism

NCT06246357

Clinical

Trials by Indication[1]

Hyperaldosteronism1 trial

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06246357·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [68Ga]Ga-PentixaFor. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [68Ga]Ga-PentixaFor. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

[68Ga]Ga-PentixaFor

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Hyperaldosteronism1 trial

References

Drug Info

Quick Facts

Related News